Oncology

Overview

The Oncology research area is composed by nine groups addressing the principal unsolved issues in cancer. Their research covers fields such as child and adolescent cancer, melanoma, Gynecology, Urology, cancer stem cells and the molecular mechanisms of the tumor pathologies.

There are also three groups from the CIBBIM-Nanomedicine. These groups study the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics.

Publications

120

total

757.123

impact factor

6.309

average impact factor

Director: Simón Schwartz Navarro

team

zoom

download

The group on Drug Delivery and Targeting seeks on the one hand, the identification of new disease biomarkers and therapeutic targets, with special focus on cancer molecular pathways and in the physiopathology of low prevalent diseases; and on the other hand, the development of new drug delivery strategies as applied nanomedicine, with a particular interest into new targeting approaches for clinical applications.

Several in vitro and in vivo cancer models have been generated by the group for preclinical testing of nanomedicines, including the generation of specific bioluminescent cancer stem cell models. Further, we have generated new polymer nanoconjugates against metastatic cancer showing no toxicity profiles, high in vivo efficacy and industrial transferability. A total of 14 patents have been issued by our group. Three patents from the group are either issued or advanced to National Fases.

11

total

46^.587

impact factor

4^.235

average impact factor

SELECTED ARTICLES

Diana Rafael, Francesc Martínez, Fernanda Andrade, Joaquim Seras-Franzoso, Natalia Garcia-Aranda, Pertra Gener, Joan sayós, Diego Arango, Ibane Abasolo, Simó Schwartz Jr.
Efficient EFGR mediated siRNA delivery to Breast Cancer Cells by Cetuximab Functionalized Pluronic ® F127/Gelatin.
Chemical Engineering Journal
https://doi.org/10.1016/j.cej.2017.12.114
IF: 6,216
Kandhaya-Pillai R, Miro-Mur F, Alijotas-Reig J, Tchkonia T, Kirkland JL, Schwartz S Jr.
TNF?-Senescence Initiates a STAT-Dependent Positive Feedback Loop, Leading to a Sustained Interferon Signature, DNA Damage, and Cytokine Secretion.
Aging-US, 2017 Nov 22;9(11):2411-2435
doi: 10.18632/aging.101328.
IF: 4,867
Rocas P, Fernández Y, García-Aranda N, Foradada L, Calvo P, Avilés P, Guillén MJ, Schwartz S Jr., Rocas J, Albericio F, Abasolo, I.
Improved Pharmacokinetic Profile of Lipophilic Anti-Cancer Drugs Using ???3-targeted Polyurethane-Polyurea Nanoparticles.
Nanomedicine-NBM.
doi: 10.1016/j.nano.2017.10.009. Epub 2017 Nov 7.
IF: 5,671
Mateo-Lozano S, Bazzocco S, Rodrigues P, Mazzolini R, Andretta E, Dopeso H, Fernández Y, Del Llano E, Bilic J, Suárez-López L, Macaya I, Cartón-García F, Nieto R, Jimenez-Flores LM, de Marcondes PG, Nuñez Y, Afonso E, Cacci K, Hernández-Losa J, Landolfi S, Abasolo I, Ramón Y Cajal S, Mariadason JM, Schwartz S Jr, Matsui T, Arango D.
Loss of the EPH receptor B6 contributes to colorectal cancer metastasis.
Sci Rep. 2017 Mar 6;7:43702.
doi: 10.1038/srep43702. PMID: 28262839
IF: 5,228
Schwartz S Jr Unmet needs in developing nanoparticles for precision medicine.
Nanomedicine (Lond). 2017 Feb;12(4):271-274
doi: 10.2217/nnm-2016-0390.
IF: 4,889

View all publications

Oncology

Overview

Publications

Director: Simón Schwartz Navarro

Research Areas